Efficacy and tolerability of three regimens for Helicobacter pylori eradication -: A multicentre, double-blind, randomised clinical trial

被引:4
作者
Bujanda, L
Herrerias, JM
Ripollés, V
Pena, D
Chaves-da-Cruz, A
Teixeira, C
Company, T
Fueyo, A
机构
[1] Glaxo Wellcome Espana SA, Dept Med, Gastroenterol Unit, E-28760 Madrid, Spain
[2] Hosp San Eloy, Dept Gastroenterol, Baracaldo, Spain
[3] Hosp Virgen de la Macarena, Dept Gastroenterol, Seville, Spain
[4] Gen Hosp, Dept Gastroenterol, Castellon de La Plana, Spain
[5] Hosp Distrital, Dept Gastroenterol, Figueira Da Foz, Portugal
[6] Hosp Distrital, Dept Gastroenterol, Chaves, Portugal
[7] Glaxo Wellcome, Dept Med, Lisbon, Portugal
关键词
D O I
10.2165/00044011-200121010-00001
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Objective: Helicobacter pylori plays a pivotal role in gastroduodenal disease. Ranitidine bismuth citrate (RBC)-based triple therapies for a period of 7 days have proven to be an effective treatment for H. pylori. The aim of this study was to compare the eradication efficacy and tolerability profile of a 7-day course of RBC plus clarithromycin and amoxicillin, RBC plus clarithromycin, and omeprazole plus clarithromycin and amoxicillin. Design: Prospective, randomised, double-blind, multicentre study. Methods: A total of 154 H. pylori-positive patients with dyspeptic symptoms were randomised to RBC 400mg twice daily (bid) plus clarithromycin 500mg bid and amoxicillin Ig bid (RBCCA group, n = 53); RBC 400mg bid plus clarithromycin 500mg bid (RBCC group, n = 52); or omeprazole 20mg bid plus clarithromycin 500mg bid and amoxicillin Ig bid (OCA group, n = 49) administered for 7 days. H. pylori infection was initially detected on an antral biopsy by the rapid urease test and confirmed by C-13-urea breath test. H. pylori status was assessed by C-13-urea breath test at least 28 days after the end of treatment. Results: There were no statistically significant differences in eradication rates per intention-to-treat (ITT) analysis (n = 149) and per protocol (PP) analysis (n = 135) among the three regimens. Eradication rates per ITT were 82.6% [95% confidence interval (CI), 69.2 to 92%] for RBCCA; 82% (95% CI, 68.7 to 91.9%) for RBCC; and 72.3% (95% CI, 57.7 to 85.6%) for OCA. The corresponding figures for the PP analysis were 85.1% (95% CI, 71.1 to 93.1%), 83% (95% CI, 68.7 to 91.9%), and 73.2% (95% CI, 56.8 to 85.2%), respectively. All regimens were well tolerated. Adverse events occurred in 59 (38%) of the 154 patients and included minor gastrointestinal symptoms and neurological complaints (anxiety, insomnia and headache). Conclusions: The results of this study suggest that the best approach to eradicate H. pylori may be the combination of ranitidine bismuth citrate with clarithromycin either with or without amoxicillin.
引用
收藏
页码:1 / 7
页数:7
相关论文
共 30 条
[1]  
ALARCON T, 1996, REV ESP QUIMOTER, V9, P138
[2]   Ranitidine bismuth citrate and clarithromycin twice daily in the eradication of Helicobacter pylori [J].
Axon, ATR ;
Ireland, A ;
Law-Smith, MJ ;
Roopram, PD .
ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 1997, 11 (01) :81-87
[3]  
Bardhan KD, 1998, AM J GASTROENTEROL, V93, P380, DOI 10.1111/j.1572-0241.1998.00380.x
[4]  
Cammarota G, 2000, ALIMENT PHARM THERAP, V14, P73
[5]  
Cammarota G, 1998, ALIMENT PHARM THERAP, V12, P539, DOI 10.1046/j.1365-2036.1998.00341.x
[6]  
CHIBA N, 1992, AM J GASTROENTEROL, V87, P1716
[7]  
Comet R, 1998, Gastroenterol Hepatol, V21, P81
[8]  
de Boer WA, 1998, AM J GASTROENTEROL, V93, P1101, DOI 10.1111/j.1572-0241.1998.00337.x
[9]  
Fleiss JL, 1981, STAT METHODS RATES P
[10]  
Forné M, 1998, AM J GASTROENTEROL, V93, P35, DOI 10.1111/j.1572-0241.1998.035_c.x